{"id":543178,"date":"2021-05-13T18:44:01","date_gmt":"2021-05-13T18:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543178"},"modified":"2021-05-13T18:44:01","modified_gmt":"2021-05-13T18:44:01","slug":"diabetic-macular-edema-dme-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-macular-edema-dme-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis_543178.html","title":{"rendered":"Diabetic Macular Edema (DME) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Macular Edema (DME) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Diabetic Macular Edema (DME) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Diabetic Macular Edema (DME) Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Macular Edema (DME) Market. <\/div>\n<p style=\"text-align: justify;\">The Diabetic Macular Edema (DME) Pipeline report embraces in-depth commercial and clinical assessment of the Diabetic Macular Edema (DME) pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema (DME) collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-macular-edema-dme-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/diabetic-macular-edema-dme-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Diabetic Macular Edema (DME) Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/2c6dca2d7d0bd4b9a32a01a994012426.jpg\" alt=\"Diabetic Macular Edema (DME) Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Research is underway to identify treatment approaches that may address some of the challenges to existing treatment. Some of the key players at the global level are involved in developing therapies for the treatment of Diabetic Macular Edema.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Macular Edema (DME) Companies:<\/strong><br \/>Novartis<br \/>Roche<br \/>Graybug Vision<br \/>YD Global Life Science Co.<br \/>Momenta Pharmaceuticals<br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-macular-edema-dme-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Diabetic Macular Edema (DME) Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Macular Edema (DME) with aggregate therapies developed by each company for the same.<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Diabetic Macular Edema (DME) Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Diabetic Macular Edema (DME) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Diabetic Macular Edema (DME) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Macular Edema (DME) market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Macular Edema (DME) Therapies covered in the report include:<\/strong><br \/>Brolucizumab<br \/>Faricimab<br \/>MYL-1701P<br \/>GB-102<br \/>YD-312<br \/><strong>And many more.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Diabetic Macular Edema (DME).&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the Diabetic Macular Edema (DME) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Macular Edema (DME) Research &amp; Development. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the Diabetic Macular Edema (DME) treatment market. Several potential therapies for Diabetic Macular Edema (DME) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Diabetic Macular Edema (DME) market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the Diabetic Macular Edema (DME) pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Diabetic Macular Edema (DME)&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Diabetic Macular Edema (DME) Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Diabetic Macular Edema (DME) &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Diabetic Macular Edema (DME) Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Diabetic Macular Edema (DME) Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Diabetic Macular Edema (DME) Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Diabetic Macular Edema (DME) Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Diabetic Macular Edema (DME) Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Diabetic Macular Edema (DME) Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Diabetic Macular Edema (DME) Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Diabetic Macular Edema (DME) Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Diabetic Macular Edema (DME) Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-macular-edema-dme-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/diabetic-macular-edema-dme-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Latest Reports By DelveInsight<\/strong><br \/><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-macular-edema-dme-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Diabetic Macular Edema (DME) Market<br \/><\/a><\/strong>DelveInsight&#8217; s Diabetic Macular Edema (DME) &#8211; Market Insights, Epidemiology and Market Forecast &#8211; 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the market forecast in the 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/electroencephelographs-eeg-pipeline-insight-and-competitive-landscape\">Electroencephelographs (EEG) Pipeline Insight<br \/><\/a><\/strong>DelveInsight&rsquo;s, &ldquo;Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020,&rdquo; report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. The report provides a detailed study of the emerging Electroencephelographs devices along with competitive landscape to help better understand the emerging Electroencephelographs devices and also covers the present clinical development scenario and growth prospects across Electroencephelographs (EEG) market.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-macular-edema-dme-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-macular-edema-dme-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;Diabetic Macular Edema (DME) Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Macular Edema (DME) Market. The Diabetic Macular Edema (DME) Pipeline report embraces &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-macular-edema-dme-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis_543178.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-543178","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543178"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543178\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}